25/05/2026
ESMO 2025 summary
🔔 Breaking News from ESMO 2025 (Berlin, Oct 17–21)
Key highlights across breast, prostate, lung, and sarcoma — all condensed for expert readers
⸻
🩷 BREAST CANCER
🧬 1️⃣ Adjuvant CDK4/6 inhibitors show durable survival benefit (monarchE & NATALEE)
• monarchE (LBA13):
• 7-year OS: HR 0.842 (p = 0.0273) → 15.8% risk reduction in death.
• 7-year IDFS HR 0.734; DRFS HR 0.746 (p < 0.0001).
• 26.6% ↓ risk of invasive recurrence.
• NATALEE (LBA14):
• 5-year IDFS HR 0.716 (p < 0.0001).
• OS trend HR 0.80 (p = 0.026).
• Benefit seen even in node-negative high-risk population.
• Interpretation: Adjuvant CDK4/6 inhibition (abemaciclib or ribociclib) + ET confirms long-term disease control with early OS signal.
⸻
💊 2️⃣ SGNTUC-019: Tucatinib + Trastuzumab effective for HER2-mutated MBC
• Final ORR 41.9%; median DOR 18.2 mo; PFS 10.9 mo; OS 32.7 mo.
• Excellent tolerability (6% discontinuation, no treatment-related deaths).
• Highlights HER2 mutations in lobular histology as important target.
⸻
💉 3️⃣ APHINITY final OS: Dual HER2 blockade works in node-positive disease
• 11.3-yr follow-up: 10-yr OS 91.6% vs 89.8%; HR 0.83 (p = 0.044).
• Benefit limited to node-positive and HR+ tumors.
• Confirms pertuzumab + trastuzumab + chemo as standard for high-risk EBC.
⸻
🌸 4️⃣ TROPION-Breast01 final: Dato-DXd maintains durable PFS advantage
• OS not significant (HR 1.01), but PFS2, TFST, and QoL favour Dato-DXd.
• Adjusted HR 0.86 after subsequent ADC use imbalance.
• Safety manageable; half the rate of grade ≥3 AEs vs chemo.
• Takeaway: Dato-DXd remains a valuable post-chemo option for HR+/HER2- MBC, but T-DXd still dominates HER2-low space.
⸻
🧠 5️⃣ KEYNOTE-756 update: Pembrolizumab + NACT in ER+/HER2- EBC
• pCR 24.3% vs 15.6% (p < 0.01).
• Stronger effect with PD-L1 ≥ 10% and ER < 10%.
• No new safety concerns; EFS pending.
• First signal that immunotherapy may improve chemo efficacy in luminal high-risk disease.
⸻
🔥 6️⃣ ABIGAIL trial: Abemaciclib + ET vs chemo in aggressive HR+/HER2– ABC
• ORR at 12 weeks: 58.8% vs 40.2% (p = 0.019).
• Indicates CDK4/6i can be as fast-acting as chemo for visceral crisis-like cases.
• Safety consistent with known profiles.
⸻
🖤 7️⃣ Triple-Negative Breast Cancer – new frontiers
• Ivonescimab + Taxane: ORR 72%, DCR 100% (China).
• PM8002/BNT327 + Nab-Paclitaxel: ORR 73.8%, median PFS 13.5 mo.
• Triple-B Study: Paclitaxel + Atezolizumab → best PFS (6.5 mo); preferable backbone for PD-L1 ≥ 10%.
• Message: Dual PD-L1 + VEGF targeting emerging as next-gen IO for TNBC.
⸻
🩸 OTHER TUMOURS
🔷 RC48-C016: ADC + IO revolution in urothelial cancer
• Disitamab Vedotin + Toripalimab vs chemo:
• OS 31.5 vs 16.9 mo (HR 0.54, p < 0.0001)
• PFS 13.1 vs 6.5 mo (HR 0.36)
• ORR 76% vs 50%
• Grade ≥3 AEs 55% vs 87%
• Sets new benchmark in HER2-expressing urothelial carcinoma; global validation underway.
⸻
🧬 PSMAddition + PR21: 177Lu-PSMA-617 in Prostate Cancer
• PSMAddition (mHSPC): rPFS HR 0.72 (p = 0.002); trend to OS improvement.
• PR21 (mCRPC): Docetaxel outperforms Lu-PSMA for OS (18.2 vs 14.3 mo).
• Insight: Lu-PSMA best reserved for later lines; early use still exploratory.
⸻
🫁 OptiTROP-Lung04: Sacituzumab Tirumotecan sets new standard post-EGFR TKI
• PFS 8.3 vs 4.3 mo (HR 0.49, p < 0.0001).
• OS ↓ 40% risk of death (HR 0.60, p = 0.0006).
• Confirms TROP2 as robust target post-TKI; well tolerated.
• Global TroFuse-009 ongoing.
⸻
🩸 HARMONi-6: Bispecific Ivonescimab (PD-1 + VEGF) ↑ PFS in Squamous NSCLC
• PFS 11.1 vs 6.9 mo (HR 0.60, p < 0.0001).
• Benefit across PD-L1 subgroups.
• Grade ≥3 bleeding 1.9% — surprisingly low.
• Awaits OS validation outside China.
⸻
🧩 KRAS Inhibitor Landscape: Activity with New G12C and G12D agents
• HRS-7058 (G12C): NSCLC ORR 43.5%; CRC 34%; PDAC 75%.
• HRS-4642 / INCB161734 (G12D): PDAC ORR ~20–34%; manageable safety.
• Early ctDNA response used as surrogate biomarker.
• Future: combo strategies with PD-1 and chemo planned.
⸻
🎯 ADC Frontier: Pan-Tumour Targets Emerge
• DS-3939 (anti-MUC1): CR + 10 PRs across breast, ovarian, lung; DCR > 75%; manageable ILD risk.
• ABBV-400 (anti-MET): ORR 46% across solid tumors; PFS 8.5 mo; promising in NSCLC & GEA.
• Implication: MUC1 and MET are joining HER2 and TROP2 as major ADC targets.
⸻
🎗️ SARCOMA: EFTISARC-NEO hits primary endpoint with IO + RT
• Hyalinisation/fibrosis ↑ to 51.5% vs ~15% historical.
• ORR 13%; Grade ≥3 TRAEs 20%.
• Suggests neoadjuvant RT + eftilagimod alpha + pembro induces strong immune priming.
• TLS identified as emerging biomarker of IO response (CONgRAtS study).
⸻
🩺 OVARIAN CANCER:
• ICON8B: Weekly Paclitaxel + Bevacizumab → OS 49.8 vs 39.6 mo (HR 0.79, p = 0.010).
• FZOCUS-1: Fuzuloparib + Apatinib no added benefit overall; signal in HRP subgroup.
• Confirms weekly taxane backbone advantage with Bev in high-risk EOC.
⸻
🧭 Comprehensive Summary
The 2025 ESMO Congress in Berlin delivered a powerful message of durable benefit, refined targeting, and evolving precision oncology.
Long-term data from monarchE and NATALEE finally establish CDK4/6 inhibition as a cornerstone in early HR+/HER2– breast cancer, showing sustained relapse prevention and emerging OS advantage.
Parallel advances in HER2-mutant and HER2-positive disease — from SGNTUC-019 and APHINITY — confirm the growing reach of anti-HER2 strategies beyond traditional amplification.
For metastatic HR+/HER2– disease, Dato-DXd continues to outperform chemotherapy with sustained benefit and tolerable safety,
while KEYNOTE-756 and ABIGAIL redefine the role of immunotherapy and CDK4/6 inhibitors even in aggressive luminal tumors.
Triple-negative disease saw a wave of innovation, from dual PD-L1/VEGF antibodies to optimal IO-chemo pairing in Triple-B, all pointing toward more personalized, biology-driven regimens.
Beyond breast oncology, the congress spotlighted the maturing field of
ADC-IO combinations across tumor types: RC48-C016 achieved near-doubling of OS in HER2-expressing urothelial carcinoma,
while OptiTROP-Lung04 established Sacituzumab Tirumotecan as the first ADC to improve OS in post-EGFR TKI NSCLC.
In prostate cancer, 177Lu-PSMA-617 validated its rPFS impact in mHSPC, though survival data remain immature.
Novel KRAS inhibitors (G12C and G12D) and next-generation ADCs (anti-MUC1, anti-MET) illustrate the rapid expansion of drugable oncogenic space and the move toward pan-tumor precision medicine.
Sarcoma and ovarian sessions added further depth, demonstrating the potential of IO + RT synergy (EFTISARC-NEO) and taxane-Bev optimization (ICON8B).
⸻
In summary:
➡️ ESMO 2025 marks a turning point — long-term proof of adjuvant CDK4/6 benefit, ADC dominance beyond HER2, and cross-tumor integration of immunotherapy and radiopharmaceuticals.
The next oncology era is defined by precision, durability, and mechanistic synergy — from CDK to ADC.
Courtesy-Mohammad Sabry Al lady.
